Bio News
Dr. Oregonin, an alder extract-based gum biomaterial, has achieved four nationally recognized distinctions, including selection for the “Innovation Premier 1000.” The material demonstrated anti-inflammatory activity in human gum cells and received NET certification. The company plans to enter the health functional food and botanical drug markets, beginning with oral care products.
BIOBOOK TEAM
biobookmedia@biobook.co.krAsahi Kasei Wins FDA Approval for New Herpes Drug Hovlpri for Immunocompromised Adults
Mirum’s Livmarli succeeds in phase 3 trial, company seeks expanded indication for rare liver disease
Roche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
